CONMED (CNMD) Projected to Post Earnings on Wednesday

CONMED (NYSE:CNMD) is expected to release its Q4 2025 results after the market closes on Wednesday, January 28th. Analysts expect the company to announce earnings of $1.32 per share and revenue of $366.8820 million for the quarter. CONMED has set its FY 2025 guidance at 4.480-4.530 EPS. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, January 28, 2026 at 4:30 PM ET.

CONMED (NYSE:CNMD) last announced its earnings results on Wednesday, November 5th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. CONMED had a return on equity of 14.22% and a net margin of 4.75%.The business had revenue of $337.93 million during the quarter, compared to analyst estimates of $334.76 million. During the same period last year, the company earned $1.05 EPS. CONMED’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Price Performance

Shares of CNMD opened at $41.64 on Wednesday. The business has a 50-day moving average of $41.66 and a 200-day moving average of $46.95. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.10 and a quick ratio of 0.95. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of 20.31, a price-to-earnings-growth ratio of 1.87 and a beta of 0.96. CONMED has a 1 year low of $38.32 and a 1 year high of $74.70.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CNMD. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CONMED in a research report on Wednesday, October 8th. Wells Fargo & Company cut their target price on CONMED from $57.00 to $47.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 6th. Bank of America decreased their target price on CONMED from $65.00 to $52.00 and set a “neutral” rating for the company in a research report on Monday, December 8th. JPMorgan Chase & Co. lowered their price objective on shares of CONMED from $58.00 to $52.00 and set a “neutral” rating on the stock in a research report on Thursday, November 6th. Finally, Piper Sandler reduced their price objective on CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $53.67.

Institutional Investors Weigh In On CONMED

A number of institutional investors and hedge funds have recently modified their holdings of CNMD. Wasatch Advisors LP bought a new stake in shares of CONMED during the 3rd quarter worth $47,026,000. Dimensional Fund Advisors LP raised its position in CONMED by 19.8% during the third quarter. Dimensional Fund Advisors LP now owns 1,296,776 shares of the company’s stock valued at $60,984,000 after purchasing an additional 214,126 shares in the last quarter. Millennium Management LLC bought a new stake in CONMED during the third quarter worth about $9,239,000. Two Sigma Investments LP lifted its stake in CONMED by 150.3% during the third quarter. Two Sigma Investments LP now owns 164,437 shares of the company’s stock worth $7,733,000 after purchasing an additional 98,729 shares during the last quarter. Finally, Qube Research & Technologies Ltd boosted its holdings in shares of CONMED by 268.5% in the 3rd quarter. Qube Research & Technologies Ltd now owns 104,838 shares of the company’s stock worth $4,931,000 after purchasing an additional 76,386 shares in the last quarter.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.